Int'l : +1-503-894-6022 | Toll Free : +1-800-792-5285 | help@alliedmarketresearch.com
A47407 | Pages: 158 | Charts: 56 | Tables: 40 |
The U.S. carrier screening market size was valued at $585.46 Million in 2021 and is projected to reach $2,147.24 Million by 2031, registering a CAGR of 14.4% from 2022 to 2031. There are a number of inherited conditions which can be screened for in the general population. Genetic screening tests can detect carriers for an inherited condition even though a woman and her partner do not have a family history of the condition.
Carrier screening is typically performed for genetic diseases in which both parents must be carriers in order to have an affected child. Carrier screening determines whether or not an individual carries a change in one of their genes and if they are at increased risk of having a child affected with a genetic disease. Everyone carries abnormal genes, and in general, carriers have no symptoms or signs of the disease they carry. Carrier screening typically involves a blood test from one or both parents and can be performed when planning a pregnancy or after a woman has become pregnant.
Historical Overview
The market was analyzed qualitatively and quantitatively from 2018-2020. Most of the growth during this period was derived owing to the rise in the prevalence of genetic diseases and the increase in the adoption of carrier screening kits in the early diagnosis of genetic disease, improving health awareness, rising disposable incomes, as well as the well-established presence of domestic companies in the region.
Market Dynamics
The rise in the prevalence of genetic and chromosomal diseases such as fragile x syndrome, spinal muscular atrophy, alpha thalassemia, cystic fibrosis, and various others and the rise in technological advancement for the development of the latest carrier screening kits and devices boost the growth of the U.S. carrier screening market. For instance, according to the report published by the Centers for Disease Control and Prevention, in November 2022, it has been reported that down syndrome remains the most common chromosomal condition diagnosed in the U.S. each year, as about 6,000 babies born in the U.S. have down syndrome. This means that down syndrome occurs in about 1 in every 700 babies.
The surge in the growing demand for the early detection of genetic disorders among the population and wide access to advanced screening techniques propels the growth of the market. The growth of the U.S. carrier screening market is expected to be driven by the rise in awareness about the importance of early detection of genetic disorders, and an increase in the demand for tele consultancy services. Moreover, the increase in the number of R&D activities in the field of carrier screening kits or medical devices enhanced healthcare services, and significant investments by the government to improve healthcare infrastructure has become vital tool for small and large businesses that propel the growth of the market.
On February 2019, Invitae Corporation launched the addition of non-invasive prenatal screening (NIPS) to the company's comprehensive women's health genetic testing services, providing patients with easier access to affordable genetic testing in early pregnancy. In combination with the expanded carrier screening (ECS), Invitae also offers integrated testing using the two most common prenatal genetic tests, with in-depth follow-up testing.
The outbreak of COVID-19 has disrupted workflows in the healthcare sector around the world. The disease has forced several industries to shut their doors temporarily, including several sub-domains of health care. The U.S. carrier screening market experienced a decrease in 2020 owing to the disrupted healthcare services including genetic counseling, which resulted in a reduction in the patient influx to genetic counselors and workforce shortages to perform the essential functions required of newborn screening (NBS) programs.
The market is anticipated to witness steady growth in 2021 and is anticipated to grow at a significant CAGR during the forecast period for the U.S. carrier screening market. This is attributed to the increasing shift towards the telehealth consultancy program. Moreover, prior to the COVID‐19 pandemic, samples were collected by clinic staff and/or phlebotomy technicians immediately following the genetic counseling appointment. But, with the implementation of direct-to-patient (D2P) telehealth visits due to COVID‐19, now patients had the option to either go to an independent phlebotomy clinic or elect mobile phlebotomy services through the genetic testing laboratory.
The U.S. carrier screening market is segmented on the basis of type, technology, and end user. By type, the market is segmented into expanded carrier screening and targeted disease carrier screening. The expanded carrier screening segment is further divided into customized panel testing and predesigned panel testing. As per technology, it is bifurcated into DNA sequencing, polymerase chain reaction, microarrays, and others. According to the end user, the market is segmented into hospitals & clinics, reference laboratories, physician offices, and others.
[TYPEGRAPH]
By type: based on type, the market is segmented into expanded carrier screening and targeted disease carrier screening. In 2021, the expanded carrier screening segment accounted for the largest share of the market. The dominance of this segment can be attributed to rising awareness about the importance of carrier screening tests by pregnant women for determining the chances or risk of a child inheriting genetic disorders from the parents, increasing the demand for expanded carrier screening.
[TECHNOLOGYGRAPH]
By technology: by technology U.S. carrier screening market is segregated into DNA sequencing, polymerase chain reaction, microarrays, and others. In 2021, the DNA sequencing segment accounted for the largest share of the market. The dominance of this segment can be attributed to the benefits offered by this technique including its precise accuracy is one of the main factors that define the utility of a genetic carrier testing workflow in a clinical laboratory boosts the growth of the market.
[BYENDUSERPHARMACEUTICALSINDUSTRYGRAPH]
By end user: by end user, the U.S. carrier screening market is segregated into hospitals & clinics, reference laboratories, physician offices, and others. The hospitals & clinics segment exhibited the highest growth in 2021 and is anticipated to lead during the forecast period, owing to improving healthcare facilities, facilities for medical and surgical treatment as well as nursing care to patients, physical rehabilitation post surgeries, and the availability of advanced equipment are the key factors that drive the growth of the market in upcoming years.
Competition Analysis
Competitive analysis and profiles of the major players in the U.S. carrier screening market, such as Fulgent Genetics Inc., Invitae Corporation, Illumina Inc., PerkinElmer Inc., Myriad Genetics, Inc., Natera Inc., LabCorp, Quest Diagnostics Incorporated, Thermo Fisher Scientific, Inc., and Sema4 are provided in this report. Major players have adopted product launch, product expansion, and acquisition as key developmental strategies to improve the product portfolio of the U.S. carrier screening pregnancy market.
Some examples of product launches in the market
Product launch in the market
In September 2022, Illumina, Inc. launched NovaSeq 6000 Dx as the first FDA-registered and CE-marked in vitro diagnostic (IVD) high-throughput sequencer and NovaSeq X Series (NovaSeq X and NovaSeq X Plus), with revolutionary new production-scale sequencers.
In August 2020, Quest Diagnostics launched automated Next Generation Sequencing (NGS) engine to power AncestryHealth. A new innovation in advanced genetic sequencing automation from Quest Diagnostics enables individuals to access highly accurate genetic testing providing insights into inherited diseases including cancers of the breast, colon, and other conditions through AncestryHealth.
In July 2020 Illumina, Inc. launched TruSight software bringing turn-key data analysis solutions to accelerate and facilitate the adoption of whole-genome sequencing with the launch of the new software suite. TruSight Software delivers ready-made infrastructure to realize the full potential of whole-genome sequencing for rare genetic diseases.
Key Market Segments
Key Market Players
CHAPTER 1:INTRODUCTION
1.1.Report description
1.2.Key benefits for stakeholders
1.3.Key market segments
1.4.Research methodology
1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models
CHAPTER 2:EXECUTIVE SUMMARY
2.1.Key findings of the study
2.2.CXO perspective
CHAPTER 3:MARKET LANDSCAPE
3.1.Market definition and scope
3.2.Key findings
3.2.1.Top investment pockets
3.3.Porter’s five forces analysis
3.4.Market dynamics
3.4.1.Drivers
3.4.1.1.Increase in the prevalence of genetic disorders
3.4.1.2.Rise in technological advancement
3.4.1.3.Rise in awareness for early disease diagnosis
3.4.2.Restraints
3.4.2.1.High cost associated with carrier screening and dearth of skilled professionals
3.4.3.Opportunity
3.4.3.1.Rise in the number of R&D investment by pharmaceutical companies
3.4.4.Impact analysis
3.5.Impact analysis of COVID-19 on the U.S. carrier screening market
CHAPTER 4:U.S. CARRIER SCREENING MARKET, BY TYPE
4.1.Overview
4.1.1.Market size and forecast
4.2.Expanded carrier screening
4.2.1.Key market trends, growth factors, and opportunities
4.2.2.Market size and forecast
4.2.2.1.Customized panel testing
4.2.2.2.Predesigned panel testing
4.3.Targeted disease carrier screening
4.3.1.Key market trends, growth factors, and opportunities
4.3.2.Market size and forecast
CHAPTER 5:U.S. CARRIER SCREENING MARKET, BY TECHNOLOGY
5.1.Overview
5.1.1.Market size and forecast
5.2.DNA sequencing
5.2.1.Market size and forecast
5.3.Polymerase chain reaction
5.3.1.Market size and forecast
5.4.Microarrays
5.4.1.Market size and forecast
5.5.Others
5.5.1.Market size and forecast
CHAPTER 6:U.S. CARRIER SCREENING MARKET, BY END USER
6.1.Overview
6.1.1.Market size and forecast
6.2.Hospitals & clinics
6.2.1.Market size and forecast
6.3.Reference laboratories
6.3.1.Market size and forecast
6.4.Physician offices
6.4.1.Market size and forecast
6.5.Others
6.5.1.Market size and forecast
CHAPTER 7:COMPETITION LANDSCAPE
7.1.Top winning strategies
7.2.Product mapping
7.3.Competitive dashboard
7.4.Competitive heatmap
7.5.Key developments
7.5.1.Product Launch
7.5.2.Collaboration
7.5.3.Acquisition
7.5.4.Partnership
7.5.5.Agreement
7.6.Top Player Positioning 2021 (10 Players)
CHAPTER 8:COMPANY PROFILES
8.1.FULGENT GENETICS INC.
8.1.1.Company overview
8.1.2.Company snapshot
8.1.3.Operating business segments
8.1.4.Product portfolio
8.1.5.Business performance
8.1.6.Key strategic moves and developments
8.2.INVITAE CORPORATION
8.2.1.Company overview
8.2.2.Company snapshot
8.2.3.Operating business segments
8.2.4.Product portfolio
8.2.5.Business performance
8.2.6.Key strategic moves and developments
8.3.ILLUMINA, INC.
8.3.1.Company overview
8.3.2.Company snapshot
8.3.3.Operating business segments
8.3.4.Product portfolio
8.3.5.Business performance
8.3.6.Key strategic moves and developments
8.4.LABCORP
8.4.1.Company overviews
8.4.2.Company snapshot
8.4.3.Operating business segments
8.4.4.Product portfolio
8.4.5.Business performance
8.4.6.Key strategic moves and developments
8.5.MYRIAD GENETICS INC.
8.5.1.Company overview
8.5.2.Company snapshot
8.5.3.Operating business segments
8.5.4.Product portfolio
8.5.5.Business performance
8.5.6.Key strategic moves and developments
8.6.NATERA INC.
8.6.1.Company overview
8.6.2.Company snapshot
8.6.3.Operating business segments
8.6.4.Product portfolio
8.6.5.Business performance
8.6.6.Key strategic moves and developments
8.7.PERKINELMER INC.
8.7.1.Company overview
8.7.2.Company snapshot
8.7.3.Operating business segments
8.7.4.Product portfolio
8.7.5.Business performance
8.8.SEMA4
8.8.1.Company overview
8.8.2.Company snapshot
8.8.3.Operating business segments
8.8.4.Product portfolio
8.8.5.Business performance
8.8.6.Key strategic moves and developments
8.9.QUEST DIAGNOSTICS INCORPORATED
8.9.1.Company overview
8.9.2.Company snapshot
8.9.3.Operating business segments
8.9.4.Product portfolio
8.9.5.Business performance
8.9.6.Key strategic moves and developments
8.10.THERMO FISHER SCIENTIFIC, INC.
8.10.1.Company overview
8.10.2.Company snapshot
8.10.3.Operating business segments
8.10.4.Product portfolio
8.10.5.Business performance
LIST OF TABLES
TABLE 01.U.S. CARRIER SCREENING MARKET, BY TYPE, 2021–2031 ($MILLION)
TABLE 02.U.S. CARRIER SCREENING MARKET, BY TECHNOLOGY, 2021–2031 ($MILLION)
TABLE 03.U.S. CARRIER SCREENING MARKET, BY END USER, 2021–2031 ($MILLION)
TABLE 04.FULGENT: COMPANY SNAPSHOT
TABLE 05.FULGENT: OPERATING SEGMENTS
TABLE 06.FULGENT: PRODUCT PORTFOLIO
TABLE 07.FULGENT: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 08.INVITAE: COMPANY SNAPSHOT
TABLE 09.INVITAE: OPERATING SEGMENTS
TABLE 10.INVITAE: PRODUCT PORTFOLIO
TABLE 11.ILLUMINA: COMPANY SNAPSHOT
TABLE 12.ILLUMINA: OPERATING SEGMENTS
TABLE 13.ILLUMINA: PRODUCT PORTFOLIO
TABLE 14.LABCORP: COMPANY SNAPSHOT
TABLE 15.LABCORP: OPERATING SEGMENTS
TABLE 16.LABCORP: PRODUCT PORTFOLIO
TABLE 17.MYRIAD: COMPANY SNAPSHOT
TABLE 18.MYRIAD: OPERATING SEGMENTS
TABLE 19.MYRIAD: PRODUCT PORTFOLIO
TABLE 20.MYRIAD: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 21.NATERA: COMPANY SNAPSHOT
TABLE 22.NATERA: OPERATING SEGMENTS
TABLE 23.NATERA: PRODUCT PORTFOLIO
TABLE 24.PERKINELMER INC.: COMPANY SNAPSHOT
TABLE 25.PERKINELMER INC.: OPERATING SEGMENT
TABLE 26.PERKINELMER INC.: PRODUCT PORTFOLIO
TABLE 27.SEMA4: COMPANY SNAPSHOT
TABLE 28.SEMA4: PRODUCT PORTFOLIO
TABLE 29.QUEST DIAGNOSTICS: COMPANY SNAPSHOT
TABLE 30.QUEST DIAGNOSTICS: OPERATING SEGMENTS
TABLE 31.QUEST DIAGNOSTICS: PRODUCT PORTFOLIO
TABLE 32.QUEST DIAGNOSTICS: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 33.THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT
TABLE 34.THERMO FISHER SCIENTIFIC: OPERATING SEGMENTS
TABLE 35.THERMO FISHER SCIENTIFIC: PRODUCT PORTFOLIO
LIST OF FIGURES
FIGURE 01.EXECUTIVE SUMMARY
FIGURE 02.U.S. CARRIER SCREENING MARKET SEGMENTATION
FIGURE 03.TOP INVESTMENT POCKETS
FIGURE 04.MODERATE TO HIGH BARGAINING POWER OF SUPPLIERS
FIGURE 05.HIGH BARGAINING POWER OF BUYERS
FIGURE 06.MODERATE THREAT OF SUBSTITUTES
FIGURE 07.HIGH THREAT OF NEW ENTRANTS
FIGURE 08.MODERATE INTENSITY OF RIVALRY
FIGURE 09.IMPACT ANALYSIS
FIGURE 10.U.S. CARRIER SCREENING MARKET, BY TYPE, 2021–2031 (%)
FIGURE 11.MARKET SIZE AND FORECAST OF U.S. CARRIER SCREENING MARKET FOR EXPANDED CARRIER SCREENING, 2022-2031.
FIGURE 12.MARKET SIZE AND FORECAST OF U.S. CARRIER SCREENING MARKET FOR TARGETED DISEASE CARRIER SCREENING, 2022-2031.
FIGURE 13.U.S. CARRIER SCREENING MARKET, BY TECHNOLOGY, 2021–2031 (%)
FIGURE 14.MARKET SIZE AND FORECAST OF U.S. CARRIER SCREENING MARKET FOR DNA SEQUENCING, 2022-2031.
FIGURE 15.MARKET SIZE AND FORECAST OF U.S. CARRIER SCREENING MARKET FOR POLYMERASE CHAIN REACTION, 2022-2031.
FIGURE 16.MARKET SIZE AND FORECAST OF U.S. CARRIER SCREENING MARKET FOR MICROARRAYS, 2022-2031.
FIGURE 17.MARKET SIZE AND FORECAST OF U.S. CARRIER SCREENING MARKET FOR OTHERS, 2022-2031.
FIGURE 18.U.S. CARRIER SCREENING MARKET, BY END USER, 2021–2031 (%)
FIGURE 19.MARKET SIZE AND FORECAST OF U.S. CARRIER SCREENING MARKET FOR HOSPITALS & CLINICS, 2022-2031.
FIGURE 20.MARKET SIZE AND FORECAST OF U.S. CARRIER SCREENING MARKET FOR REFERENCE LABORATORIES, 2022-2031.
FIGURE 21.MARKET SIZE AND FORECAST OF U.S. CARRIER SCREENING MARKET FOR PHYSICIAN OFFICES, 2022-2031.
FIGURE 22.MARKET SIZE AND FORECAST OF U.S. CARRIER SCREENING MARKET FOR OTHERS, 2022-2031.
FIGURE 23.TOP WINNING STRATEGIES, 2019–2022
FIGURE 24.TOP WINNING STRATEGIES, BY DEVELOPMENT, 2019–2022
FIGURE 25.TOP WINNING STRATEGIES, BY COMPANY, 2019–2022
FIGURE 26.PRODUCT MAPPING OF TOP 10 KEY PLAYERS
FIGURE 27.COMPETITIVE DASHBOARD OF TOP 10 KEY PLAYERS
FIGURE 28.COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS
FIGURE 29.TOP PLAYER POSITIONING 2021 (10 PLAYERS)
FIGURE 30.FULGENT: NET SALES, 2019–2021 ($MILLION)
FIGURE 31.FULGENT: REVENUE SHARE BY SEGMENT, 2021 (%)
FIGURE 32.FULGENT: REVENUE SHARE BY REGION, 2021 (%)
FIGURE 33.INVITAE: NET SALES, 2019–2021 ($MILLION)
FIGURE 34.INVITAE: REVENUE SHARE BY SEGMENT, 2021 (%)
FIGURE 35.INVITAE: REVENUE SHARE BY REGION, 2021 (%)
FIGURE 36.ILLUMINA: NET SALES, 2019–2021 ($MILLION)
FIGURE 37.ILLUMINA: REVENUE SHARE BY SEGMENT, 2021 (%)
FIGURE 38.ILLUMINA: REVENUE SHARE BY REGION, 2021 (%)
FIGURE 39.LABCORP: NET SALES, 2019–2021 ($MILLION)
FIGURE 40.LABCORP: REVENUE SHARE BY SEGMENT, 2021(%)
FIGURE 41.LABCORP: REVENUE SHARE BY REGION, 2021(%)
FIGURE 42.MYRIAD: NET SALES, 2019–2021 ($MILLION)
FIGURE 43.MYRIAD: REVENUE SHARE BY SEGMENT, 2021 (%)
FIGURE 44.MYRIAD: REVENUE SHARE BY REGION, 2021 (%)
FIGURE 45.NATERA: NET SALES, 2019–2021 ($MILLION)
FIGURE 46.NATERA: REVENUE SHARE BY SEGMENT, 2021(%)
FIGURE 47.NATERA: REVENUE SHARE BY REGION, 2021(%)
FIGURE 48.PERKINELMER INC.: NET SALES, 2019–2021 ($MILLION)
FIGURE 49.PERKINELMER INC.: REVENUE SHARE BY SEGMENT, 2021 (%)
FIGURE 50.PERKINELMER INC.: REVENUE SHARE BY REGION, 2021 (%)
FIGURE 51.SEMA4: NET SALES, 2019–2021 ($MILLION)
FIGURE 52.QUEST DIAGNOSTICS: NET SALES, 2019–2021 ($MILLION)
FIGURE 53.QUEST DIAGNOSTICS: REVENUE SHARE BY SEGMENT, 2021 (%)
FIGURE 54.THERMO FISHER SCIENTIFIC: REVENUE, 2019–2021 ($MILLION)
FIGURE 55.THERMO FISHER SCIENTIFIC: REVENUE SHARE BY SEGMENT, 2021 (%)
FIGURE 56.THERMO FISHER SCIENTIFIC: REVENUE SHARE BY REGION, 2021 (%)